OCGN (Ocugen) Issuance of Debt : $30.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ocugen Issuance of Debt?

Ocugen's Issuance of Debt for the three months ended in Dec. 2024 was $30.00 Mil.

Ocugen's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 was $30.00 Mil.

Ocugen Issuance of Debt Historical Data

The historical data trend for Ocugen's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Issuance of Debt Chart

Ocugen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Issuance of Debt

Get a 7-Day Free Trial

0.92

0.50

30.00

Ocugen Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Issuance of Debt	Get a 7-Day Free Trial															-	-	-	-	30.00

Ocugen Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $30.00 Mil.

Ocugen Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Ocugen's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocugen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (NAS:OCGN) » Definitions » Issuance of Debt

Comparable Companies

Traded in Other Exchanges

OCGN:Mexico 2H51:Germany 2H51:Germany 2H51:Germany

Address

11 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.ocugen.com

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Executives

Prabhavathi Fernandes	director	114 MILTON AVENUE, CHAPEL HILL NC 27514
Kirsten Castillo	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Junge Zhang	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Quan Anh Vu	officer: CFO/CBO	22616 ERWIN STREET, WOODLAND HILLS CA 91367
Shankar Musunuri	director, officer: Chief Executive Officer	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Arun Upadhyay	officer: Chief Scientific Officer	C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355
Ramesh Kumar	director	375 PHEASANT RUN, NEWTOWN PA 18940
Uday Kompella	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Marna C Whittington	director	2959 BARLEY MILL ROAD, YORKLYN DE 19736
Jessica Crespo	officer: CAO/SVP, Finance	C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355
Sanjay Subramanian	officer: Chief Financial Officer	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Manish Potti	director	C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355
Vijay Tammara	officer: Vice President	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Suha Taspolatoglu	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Kelly Beck	officer: Vice President	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355